Tenofovir-induced leukocytoclastic vasculitis

Said A. Al-Busafi, Abdulatif Al-Suleimani, Aysha Al-Hamadani, Wasif Rasool

Research output: Contribution to journalArticle

Abstract

Tenofovir, a nucleotide analog, is one of the first-line medications recommended for the treatment of active chronic hepatitis B virus infection (CHB) and as a primary prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese woman, who was known to have inactive CHB, was diagnosed with chronic immune thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a skin rash, described as non-blanchable well-defined erythematous to violaceous papules and targetoid patches in her lower extremities. A skin biopsy showed features of LCV. The rash resolved completely within few days after replacing tenofovir with entecavir.

Original languageEnglish
Pages (from-to)429-431
Number of pages3
JournalOman Medical Journal
Volume32
Issue number5
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Tenofovir
Exanthema
Hepatitis B virus
Idiopathic Thrombocytopenic Purpura
Chronic Hepatitis B
Virus Diseases
Hepatitis B
Immunosuppression
Lower Extremity
Adrenal Cortex Hormones
Nucleotides
Biopsy
Skin
Erythema elevatum diutinum
Therapeutics

Keywords

  • Hepatitis B
  • Leukocytoclastic vasculitis
  • Tenofovir

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tenofovir-induced leukocytoclastic vasculitis. / Al-Busafi, Said A.; Al-Suleimani, Abdulatif; Al-Hamadani, Aysha; Rasool, Wasif.

In: Oman Medical Journal, Vol. 32, No. 5, 01.09.2017, p. 429-431.

Research output: Contribution to journalArticle

Al-Busafi, Said A. ; Al-Suleimani, Abdulatif ; Al-Hamadani, Aysha ; Rasool, Wasif. / Tenofovir-induced leukocytoclastic vasculitis. In: Oman Medical Journal. 2017 ; Vol. 32, No. 5. pp. 429-431.
@article{53b27640026a4920ad9ecb78b6e2df5d,
title = "Tenofovir-induced leukocytoclastic vasculitis",
abstract = "Tenofovir, a nucleotide analog, is one of the first-line medications recommended for the treatment of active chronic hepatitis B virus infection (CHB) and as a primary prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese woman, who was known to have inactive CHB, was diagnosed with chronic immune thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a skin rash, described as non-blanchable well-defined erythematous to violaceous papules and targetoid patches in her lower extremities. A skin biopsy showed features of LCV. The rash resolved completely within few days after replacing tenofovir with entecavir.",
keywords = "Hepatitis B, Leukocytoclastic vasculitis, Tenofovir",
author = "Al-Busafi, {Said A.} and Abdulatif Al-Suleimani and Aysha Al-Hamadani and Wasif Rasool",
year = "2017",
month = "9",
day = "1",
doi = "10.5001/omj.2017.80",
language = "English",
volume = "32",
pages = "429--431",
journal = "Oman Medical Journal",
issn = "1999-768X",
publisher = "Oman Medical Specialty Board",
number = "5",

}

TY - JOUR

T1 - Tenofovir-induced leukocytoclastic vasculitis

AU - Al-Busafi, Said A.

AU - Al-Suleimani, Abdulatif

AU - Al-Hamadani, Aysha

AU - Rasool, Wasif

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Tenofovir, a nucleotide analog, is one of the first-line medications recommended for the treatment of active chronic hepatitis B virus infection (CHB) and as a primary prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese woman, who was known to have inactive CHB, was diagnosed with chronic immune thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a skin rash, described as non-blanchable well-defined erythematous to violaceous papules and targetoid patches in her lower extremities. A skin biopsy showed features of LCV. The rash resolved completely within few days after replacing tenofovir with entecavir.

AB - Tenofovir, a nucleotide analog, is one of the first-line medications recommended for the treatment of active chronic hepatitis B virus infection (CHB) and as a primary prophylaxis to prevent hepatitis B reactivation in cases of immunosuppression. We report the first case of tenofovir-induced leukocytoclastic vasculitis (LCV). A 43-year-old obese woman, who was known to have inactive CHB, was diagnosed with chronic immune thrombocytopenic purpura (ITP). She was treated with corticosteroid therapy and was put on tenofovir to prevent hepatitis B virus reactivation. A month later, she developed a skin rash, described as non-blanchable well-defined erythematous to violaceous papules and targetoid patches in her lower extremities. A skin biopsy showed features of LCV. The rash resolved completely within few days after replacing tenofovir with entecavir.

KW - Hepatitis B

KW - Leukocytoclastic vasculitis

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=85030770967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030770967&partnerID=8YFLogxK

U2 - 10.5001/omj.2017.80

DO - 10.5001/omj.2017.80

M3 - Article

VL - 32

SP - 429

EP - 431

JO - Oman Medical Journal

JF - Oman Medical Journal

SN - 1999-768X

IS - 5

ER -